What we do Zydus Lifesciences Ltd is a leading Indian pharmaceutical company engaged in research, manufacturing, and marketing of formulations, biosimilars, APIs, animal healthcare and consumer wellness products. |
Founded in 1,995 |
Market share Among top 3 Indian pharma companies; 3rd largest generic company in US; strong presence in India, US, and emerging markets. |
Problem solved Develops affordable medicines, advanced biologics, vaccines, and consumer wellness products addressing unmet healthcare needs globally. |
Top clients or who we serve Serves healthcare providers, hospitals, pharmacies, and consumers globally; operates B2B and B2C in pharmaceuticals, animal health, and wellness. |
Key management Dr. Sharvil P. Patel (Managing Director) leads the company with a focus on innovation and global expansion. |
Our journey and innovations Founded in 1995, grew via key acquisitions, JV partnerships, launched India's first biosimilars, novel drugs and advanced vaccines; strong R&D focus with 8 centers. |
Where we operate Operations span India, United States, Europe, South America, Africa, Middle East, and emerging markets with manufacturing sites in India and overseas. |
Top products or what we offer Branded generics, biosimilars (e.g. Exemptia), specialty formulations, vaccines, APIs, animal health nutrition and therapeutic products, consumer wellness brands. |
Top brands Exemptia (biosimilar Adalimumab), Oxemia (anemia drug), Zycubo (Menkes disease), Comfort Click (consumer wellness), proprietary vaccines and biosimilars in US and India. |
Raw materials needed Active pharmaceutical ingredients, biologic molecules, chemicals, and natural extracts for formulations and biosimilars. |
Raw materials supplier Global and domestic suppliers adhering to quality standards; company owns API manufacturing facilities to ensure supply. |
Recurring vs cyclical contribution Majority revenue from recurring pharmaceutical sales including generics, biosimilars, and consumer wellness; some cyclical elements in new product launches. |
Our industry position Market leader in India’s formulations and biosimilars, rapidly growing US generics presence, strong in animal health and consumer wellness sectors. |
Financial highlights FY24 consolidated revenue ~Rs.198,315 million, PAT Rs.39,728 million, strong EBITDA margin ~26.5%, consistent YoY growth over 15%. |
Geographical revenue split Revenue split: India 47%, US 56%, Others 14% (numbers exceed 100% due to consolidation; mainly pharmaceuticals segment focused). |
Order book Strong product pipeline with significant research investments; multiple product approvals and launches across markets. |
Whats driving growth Product innovation, biosimilar launches, expansion in US generics, emerging markets growth, acquisitions, and strategic alliances. |
Our future plans Expand biosimilar and novel drug portfolios, increase manufacturing capacity, grow global footprint, advance R&D pipelines and vaccine development. |
Our green promise Top 3 Indian pharma in ESG ratings, improved sustainability scores, comprehensive CSR initiatives, energy conservation and waste reduction programs. |
Our people and values Over 29,000 employees globally including 1,500 scientists; culture of innovation, ethics, inclusion and continuous learning. |
Key challenges ahead Regulatory compliance risks, competition in generics, pricing pressures, supply chain constraints, and innovation pipeline execution. |
Interesting facts World’s first biosimilar launch of Adalimumab in India; first Indian pharma with approved drug for Menkes disease; leadership in oncology biosimilars. |
Risks and strategy Mitigates risks via compliance, diversified portfolio, global market presence, cost control, and investing in breakthrough technologies. |
